medigraphic.com
ISSN 1817-5996 (Electronic)

2021, Number 1

<< Back Next >>

Rev Cub de Reu 2021; 23 (1)

Evolution of the index of activity in patients with systemic sclerosis treated with cyclophosphamide and prednisone

Remedios BSE, Hernández MAA, Bairan TN

Language: Spanish
References: 22
Page:
PDF size: 447.39 Kb.


ABSTRACT

Introduction: The systemic sclerosis is an autoimmune disease of the connective tissue where the vasculopathy happens initially and persist during all the disease. The immune component starts since the inflammatory process triggers off but he diminishes until you dwell on the evolutionary course and it is substituted for fibrosis, this ends pathogenic acquires great significance in the process. The index of activity reveals a critical period of the disease.
Objective: Evaluating patients' clinical evolution of the index of activity with systemic sclerosis with the applied therapeutics.
Methods: The study was quasi-experiences (or secondary prevention). In order to determine if the therapeutic applied scheme decreases symptomatology of its systemic activity. You started in March of the 2013 to March of the 2016, with duration of 24 months. They were 31 patients that split into two groups according to the clinical stages obtained of Comprehensive Development Index. In the group to (clinical stages I and II) 16 patients and in the group B (clinical stages III and IV) 15 patients. The evolution evaluated according to variables of the instrument of evaluation the start, to the six and 12 months itself of once the therapeutic scheme was applied. The T utilized the proof itself, or exact Fisher's proof when moral values were all the same or minor to three, the statistical significance determined in p≥ 0.05 itself. The calculation of the stocking, percentage analysis, and Wilcoxon's proof to know the relation of variables through the time.
Results: The therapeutic applied scheme, previous validation, you improved the index of activity of the patients of both groups A and B that is in clinical premature and overdue stages. In the activity moderated for the group A statistical significance for system microvascular (0.023) and respiratory (0.025) to the six months, and to the 12 months’ skin (0.023) and microvascular (0.006). For the intense activity significant improvement to the six months for muscleskelettic (0.005) and rheumatoid positive factor (0.008), to the 12 months’ significant improvement for muscleskelettic (0.004); and examine of laboratory like erythrocyte sedimentation rate (0.008) circulating immune complexes (0.005), and rheumatoid factor (0.003). For the group B in the moderate activity significant improvement for respiratory system existed (0.014), and cardiovascular (0.020) that kept to the 12 months, added up its digestive system (0.008). Evident level improvement of skin (0.004), circulating immune complexes (0.008) and rheumatoid factor were caught up within the intense activity to the 12 months (0.014).
Conclusions: Improvement in the index of activity of patients with systemic sclerosis, with the therapeutic scheme applied, with clinical stability and humoral from initial stages of the disease was caught up with.


REFERENCES

  1. Fériz AR, Louis MR, Espinoza RL, Khamashta M, Cerinic MM, Sanmartí R, et al. Enfermedades inflamatorias reumatológicas. Ed. Producciones Científicas Ltda. PANLAR; 2016. p. 397-419.

  2. Remedios Batista SE, Montada Cedeño E, del Campo Avilés E, Torres Pérez L, Fernández Portelles A. Mecanismos etiopatogénicos en la esclerosis sistémica. CCM. 2016 [Acceso 22/06/2019];20(1):[aprox 11 p.] Disponible en: https://www.revcomed.sld.cu

  3. Remedios Batista SE, Montada Cedeño E, Rivas Carralero R. Caracterización clínica epidemiológica de pacientes con esclerosis sistémica en Holguín. Rev Cubana Reumatol. 2018 [Acceso 30/04/2019];20(1). Disponible en: https://www.revreumatologia.sld.cu/

  4. Vonk MC, Van den Hoogen, Van Riel PL, Valentini G. What does the clinician need to improve patient care in systemic sclerosis? Validated clinimetric criteria, useful in the early phase of systemic are lacking. Ann Rheum Dis. 2007 [Acceso 23/05/2019];66:1129-31. Disponible en: https://www.annrheumdis.com

  5. Remedios Batista SE, Rivas Carralero R, Montada Cedeño E, Reyes García D. Estadios clínicos en pacientes con esclerosis sistémica en Holguín. (Original). Rev Cubana Reumatol. 2018 [Acceso 23/12/2019];20(2). Disponible en: https://www.revreumatologia.sld.cu/

  6. Remedios Batista SE, Rivas Carralero R, Montada Cedeño E, del Campo Avilés E, Torres Pérez L. Validación de los expertos acerca de la conducta terapéutica a seguir con los pacientes con esclerosis sistémica. Rev Cubana Reumatol. 2018 Dic [Acceso 30/04/2020];20(3):e605. Disponible en: https://scieloprueba.sld.cu

  7. Reyes Llerena GA, Guibert Toledano ZM, López Cabreja G, Hernández Derivet C. Esclerosis sistémica. Evaluación clínico-epidemiológica de una serie de casos en dos centros de referencia en Cuba. Rev Cubana Reumatol. 2014 [Acceso 23/05/2020];6(1):[Aprox 12 p.]. Disponible en: http://www.revreumatologia.sld.cu

  8. Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. Semin Arthritis Rheum. 2017 [Acceso 12/01/2020];46(6):767-74. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed

  9. Hachulla E, Bagou G, Ganansia O, Lefort H, Leroy C. Esclerodermia sistémica. Francia: Centros de Referencias de Enfermedades Raras; 2017. [Acceso 25/04/2020]. Disponible en: https://www.orpha.net/data/patho/Emg/Int/es/Esclerodermia_ES_es_EMG_ORPHA801.pdf

  10. Remedios Batista SE, Rivas Carralero R, Montada Cedeño E, del Campo Avilés E, Pérez Torres L, Caselles Fajardo HL. Supervivencia en pacientes con esclerosis sistémica en la provincia de Holguín. Rev Cubana Reumatol. 2017 [Acceso 22/08/2020];19(2):[aprox 1]. Disponible en: https://www.revreumatologia.sld.cu

  11. Hernández Negrín H. ¿Son las arritmias un predictor de mortalidad en pacientes holguineros con esclerosis sistémica? Rev Cubana Reumatol. 2017 [Acceso 22/10/2020];19(3):[aprox 1]. Disponible en: https://www.revreumatologia.sld.cu

  12. Schlabs M, Pawlak-Buś K, Leszczyński P. Retrospective analysis of infection prevalence in patients with progressive systemic sclerosis treated with cyclophosphamide. J Med Science. 2015 [Acceso 25/04/2019];3(84):44-56. Disponible en: https://www.jrheum.org

  13. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 [Acceso 30/04/2020];4(9):708-719. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27469583/

  14. Hoyles RK, Ellis RW, Wellbury S. A multicenter prospective ramdomized, double blind placebo-contolled trial of corticosteroids and intravenous ciclophosphamide followed by oral azhatioprine for the treatment of pulmonary fibrosis in Scleroderma. Arthritis Rheum. 2006;54:3962-70.

  15. Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 [Acceso 12/04/2020];76:1207-18. Disponible en: https://ard.bmj.com

  16. Hassan ML; Sociedad Argentina de Dermatología. Consenso sobre esclerodermia. Actualización 2015. Buenos Aires: Sociedad Argentina de Dermatología; 2016. [Acceso 30/04/2020]. Disponible en: https://ard.bmj.com.http://www.sad.org.ar/wp-content/uploads/2016/04/CONSENSO-ESCLERODERMIA.pdf

  17. Masui Y, Asano Y, Takahashi T, Shibata S, Akamata K, N Aozasa, et al. Clinical significance of monitoring serum adiponectin levels during intravenous pulse CYC therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatology. 2013 [Acceso 25/04/2020];23(2):[aprox 1]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22610787/

  18. Pérez Campos D, Estévez del Toro M, Peña Casanovas A, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Rheumatol Clin. 2012 [Acceso 23/03/2018];8(2):58-62. Disponible en: https://www.elsevier.es/en/linksolver/pdf/pii/s1699-

  19. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol. 2003;22(4):[aprox 1]. Doi: http://doi.org/10.1007/s10067-003-0733-2

  20. Graña D, Vargas A, Bèrez A, Goñi M, Danza A. Esclerosis sistémica: forma de presentación y manejo terapéutico. Experiencia de un grupo de trabajo en Enfermedades Autoinmunes Sistémicas. Rev Urug Med Interna. 2018 [Acceso 30/04/2020];1:15-22. Disponible en: https://www.scielo.edu.uy/pdf/rumi/v3n1/2393-6797-rumi-3-01-15.pdf

  21. Mendoza FA, Nagle SJ, Lee JB, Jiménez SA. A prospective observational study of Mycophenolate Mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012 [Acceso 25/04/2020];39(6):1241-47. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed?

  22. Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017 Jul [Acceso 23/02/2020];69(7):1451-60. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/




2020     |     www.medigraphic.com